Nutaria

Company Overview

Snapshot

Founded in June 2018, Nutaria operates with 1–10 employees. The company has secured funding across one disclosed round, totaling $300,000. Nutaria is currently in advanced preclinical stages for a drug targeting early Parkinson's disease, leveraging its patented drug delivery technology.

Business overview

Nutaria is a nutraceutical R&D company focused on revolutionizing drug delivery for brain health. The company's core technology utilizes food molecules as natural carriers to deliver active ingredients directly to specific tissues or organs, enhancing absorption and effectiveness. This patented approach, composed of FDA and EFSA-approved food ingredients, aims to improve the lives of individuals with neurodegenerative conditions by focusing on early treatment and prevention. Nutaria operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drug Delivery, serving markets in North America, Europe, Japan, and Canada.

Company Intelligence Q&A

What is Nutaria's primary focus?

Nutaria is a nutraceutical R&D company focused on developing brain-targeted therapies, particularly for patients with Parkinson's disease, using a patented drug delivery system.

When was Nutaria founded?

Nutaria was founded in June 2018.

What is Nutaria's core technology?

Nutaria's core technology involves using food molecules as natural 'taxis' to deliver active ingredients directly to specific tissues or organs, improving the internalization and effectiveness of therapeutic agents.

What is the current development stage of Nutaria's Parkinson's drug?

Nutaria is currently in the advanced preclinical stages of developing a drug specifically for early Parkinson's disease.

What markets does Nutaria target?

Nutaria targets geomarkets including North America, Europe, Japan, and Canada.